News
GCC19CART Demonstrates Preliminary Antitumor Activity in Refractory mCRC 1000 667 Innovative Cellular Therapeutics

GCC19CART Demonstrates Preliminary Antitumor Activity in Refractory mCRC

This article is reprinted from OncLive. The original li…

Innovative Cellular Therapeutics Announces the Publication of Groundbreaking GCC19CART™ Study to Treat mCRC in JAMA Oncology 1000 667 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics Announces the Publication of Groundbreaking GCC19CART™ Study to Treat mCRC in JAMA Oncology

ROCKVILLE, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) —…

Innovative Cellular Therapeutics (ICT) Presented Updated Data of the China-IRB Study of GCC19CART in Metastatic Colorectal Cancer at European Society for Medical Oncology (ESMO) Congress 2023 700 900 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) Presented Updated Data of the China-IRB Study of GCC19CART in Metastatic Colorectal Cancer at European Society for Medical Oncology (ESMO) Congress 2023

ROCKVILLE, MARYLAND, October 31st, 2023 (GLOBE NEWSWIRE…

Innovative Cellular Therapeutics (ICT) Presented Data at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting 1600 1868 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) Presented Data at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

ROCKVILLE, MARYLAND, May 24th, 2023 (GLOBE NEWSWIRE) – …

Innovative Cellular Therapeutics (ICT) Presented Updated Data at the American Association for Cancer Research (AACR) Annual Meeting 1000 1500 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) Presented Updated Data at the American Association for Cancer Research (AACR) Annual Meeting

ROCKVILLE, MARYLAND, May 2nd, 2023 (GLOBE NEWSWIRE) – I…

Innovative Cellular Therapeutics (ICT) Announces First Patient Enrolled for the Company’s Phase I Trial of GCC19CART for Relapsed/Refractory Metastatic Colorectal Cancer 1366 907 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) Announces First Patient Enrolled for the Company’s Phase I Trial of GCC19CART for Relapsed/Refractory Metastatic Colorectal Cancer

ROCKVILLE, MARYLAND, August 18, 2022 (GLOBE NEWSWIRE) –…

Innovative Cellular Therapeutics (ICT) Announces Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting 1000 667 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) Announces Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

ROCKVILLE, MARYLAND, May 26th, 2022 (GLOBE NEWSWIRE) – …

Innovative Cellular Therapeutics (ICT) to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting 1000 1500 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting

ROCKVILLE, MARYLAND, May 17th, 2022 (GLOBE NEWSWIRE) – …

Innovative Cellular Therapeutics (ICT) Announces Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting   1000 667 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) Announces Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting  

Clinical Data from one research site for GCC19CART, ICT…

Innovative Cellular Therapeutics (ICT) Receives FDA Fast Track Designation for GCC19CART, its Lead Solid Tumor Candidate, in the Treatment of Patients with Relapsed or Refractory Metastatic Colorectal Cancer 1000 667 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) Receives FDA Fast Track Designation for GCC19CART, its Lead Solid Tumor Candidate, in the Treatment of Patients with Relapsed or Refractory Metastatic Colorectal Cancer

GCC19CART is an autologous CAR T therapy candidate that…

Start Typing